Heather Wakelee

Publications

• Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
  Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., & Sequist, L. V. (2015). Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer discovery, 5(7), 713-722.
• Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
  Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., & Camidge, D. R. (2015). Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 372(18), 1700-1709.
• Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
  Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., & Wakelee, H. A. (2015). Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of thoracic oncology , 10(3), 500-508.
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. Cw., & Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature medicine, 20(5), 548-554.
  
• Hormone Use, Reproductive History, and Risk of Lung Cancer The Women's Health Initiative Studies Schwartz, A. G., Ray, R. M., Cote, M. L., Abrams, J., Sokol, R. J., & Simon, M. S. (2015). Hormone Use, Reproductive History, and Risk of Lung Cancer The Women's Health Initiative Studies. JOURNAL OF THORACIC ONCOLOGY, 10(7), 1004-1013.
  
• A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies Gubens, M. A., Burns, M., Perkins, S. M., Pedro-Salcedo, M. S., Althouse, S. K., & Wakelee, H. A. (2015). A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. LUNG CANCER, 89(1), 57-60.
  
• GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer research, 35(2), 669-676.
  
• Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2015). Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung cancer , 87(1), 34-38.
  
• Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†. Wang, A., Kubo, J., Luo, J., Desai, M., Hedlin, H., & Wakelee, H. A. (2015). Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†. Annals of oncology , 26(1), 221-230.
  
• Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Das, M., & Wakelee, H. (2014). Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Translational lung cancer research, 3(6), 397-399.
  
• Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010 Cheng, I., Le, G. M., Noone, A.-M., Gali, K., Patel, M., & Gomez, S. L. (2014). Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 23(11), 2250-2265.
  
• Review of the current targeted therapies for non-small-cell lung cancer. Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. World journal of clinical oncology, 5(4), 576-587.
  
• Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors Huang, J., Ahmad, U., Antonicelli, A., Catlin, A. C., Fang, W., & Detterbeck, F. (2014). Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors. JOURNAL OF THORACIC ONCOLOGY, 9(10), 1573-1578.
  
• Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., & Wakelee, H. A. (2014). Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. CLINICAL LUNG CANCER, 15(3), 202-206.
  
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. Cw., & Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552-558.
  
• Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients Riess, J. W., Bhattacharya, N., Blenman, K. Rm., Neal, J. W., Hwang, G., & Wakelee, H. A. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 36(2), 182-186.
  
• A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., & Wakelee, H. A. (2014). A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British journal of cancer, 110(3), 602-608.
  
• Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy Padda, S. K., Burt, B. M., Trakul, N., & Wakelee, H. A. (2014). Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy. SEMINARS IN ONCOLOGY, 41(1), 40-56.
  
• [Chemotherapy definitions and policies for thymic malignancies]. Girard, N., Lal, R., Wakelee, H., Riely, G. J., & Loehrer, P. J. (2014). [Chemotherapy definitions and policies for thymic malignancies]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 17(2), 116-121.
  
• Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., & Wang, S. X. (2013). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on a chip, 14(1), 78-88.
  
• miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma Xu, Y., Zheng, M., Merritt, R. E., Shrager, J. B., Wakelee, H. A., & Hoang, C. D. (2013). miR-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma. CHEST, 144(5), 1632-1643.
  
• How do social factors explain outcomes in non-small-cell lung cancer among hispanics in california? Explaining the Hispanic paradox. Patel, M. I., Schupp, C. W., Gomez, S. L., Chang, E. T., & Wakelee, H. A. (2013). How do social factors explain outcomes in non-small-cell lung cancer among hispanics in california? Explaining the Hispanic paradox. Journal of clinical oncology , 31(28), 3572-3578.
  
• A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., & Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. CLINICAL LUNG CANCER, 14(5), 592-595.
  
• Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report Padda, S. K., Chhatwani, L., Zhou, L., Jacobs, C. D., Lopez-Anaya, A., & Wakelee, H. A. (2013). Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. ANTI-CANCER DRUGS, 24(7), 731-735.
  
• A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389-394.
  
• A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of thoracic oncology , 8(2), e17-8.
  
• A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17-E18.
  
• Aflibercept in lung cancer Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115-120.
  
• MET inhibitors in combination with other therapies in non-small cell lung cancer. Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational lung cancer research, 1(4), 238-253.
  
• Angiogenesis inhibitors. Das, M., & Wakelee, H. (2012). Angiogenesis inhibitors. Journal of thoracic oncology , 7(16), S397-8.
  
• Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge Nagpal, S., Riess, J., & Wakelee, H. (2012). Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 13(4), 491-504.
  
• A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501 Wakelee, H. A., Lee, J.-W., Hanna, N. H., Traynor, A. M., Carbone, D. P., & Schiller, J. H. (2012). A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1574-1582.
  
• A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer Clement-Duchene, C., Natale, R. B., Jahan, T., Krupitskaya, Y., Osarogiagbon, R., & Wakelee, H. A. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. LUNG CANCER, 78(1), 57-62.
  
• Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., & Diehn, M. (2012). Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 231-237.
  
• Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., & Wakelee, H. A. (2012). Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era. JOURNAL OF THORACIC ONCOLOGY, 7(9), S243-S243.
  
• How Do Social Factors Explain Outcomes In Non-small Cell Lung Cancer Among Hispanic/latinos In California? Patel, M. I., Chang, E., Gomez, S., & Wakelee, H. A. (2012). How Do Social Factors Explain Outcomes In Non-small Cell Lung Cancer Among Hispanic/latinos In California?. JOURNAL OF THORACIC ONCOLOGY, 7(9), S216-S216.
  
• A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. Ra., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604-611.
  
• ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., & Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung cancer , 77(2), 421-426.
  
• Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab Wakelee, H. A., DAHLBERG, S. E., Brahmer, J. R., Schiller, J. H., Perry, M. C., & Johnson, D. H. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. LUNG CANCER, 76(3), 410-415.
  
• How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California? Patel, M. I., Chang, E. T., Gomez, S. L., Schupp, C., & Wakelee, H. A. (2012). How do social factors explain outcomes in non-small cell lung cancer among Hispanics/Latinos in California?. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy Riess, J., Das, M. S., Frankel, P. H., Schwartz, E., Bennis, R., & Wakelee, H. A. (2012). Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., & Wakelee, H. A. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013-1020.
  
• Targeting VEGF in lung cancer Das, M., & Wakelee, H. (2012). Targeting VEGF in lung cancer. EXPERT OPINION ON THERAPEUTIC TARGETS, 16(4), 395-406.
  
• Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Riess, J. W., & Wakelee, H. A. (2012). Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clinical advances in hematology & oncology : H&O, 10(4), 226-234.
  
• A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC) Wakelee, H. A., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., & Jacobs, C. D. (2012). A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 815-824.
  
• Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., & Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231-235.
  
• A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC) Rodon, J., Jacobs, C. D., Chu, Q., Rowinsky, E. K., Lopez-Anaya, A., & Wakelee, H. A. (2012). A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 825-834.
  
• The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer Wakelee, H. A., Takimoto, C. H., Lopez-Anaya, A., Chu, Q., Middleton, G., & Rodon, J. (2012). The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(2), 563-571.
  
• Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., & Loo, B. W. (2012). Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 13(1), 52-58.
  
• XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib Pietanza, M. C., Lynch, T. J., Lara, P. N., Cho, J., Yanagihara, R. H., & Miller, V. A. (2012). XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. JOURNAL OF THORACIC ONCOLOGY, 7(1), 219-226.
  
• Current Management of Small Cell Lung Cancer Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?.
  
• Angiogenesis Inhibitors Das, M., & Wakelee, H. (2011). Angiogenesis Inhibitors. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1801-S1802.
  
• Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., & Wakelee, H. (2011). Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 12(5), 280-285.
  
• Chemotherapy Definitions and Policies for Thymic Malignancies Girard, N., Lal, R., Wakelee, H., Riely, G. J., & Loehrer, P. J. (2011). Chemotherapy Definitions and Policies for Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 6(7), S1749-S1755.
  
• MAINTENANCE BEVACIZUMAB MONOTHERAPY INCREASES HEMOGLOBIN (HGB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG ADENOCARCINOMA (NSCLC-AD) Riess, J. W., Logan, A., Krupitskaya, Y., Clement-Duchene, C., Kuo, C., & Wakelee, H. (2011). MAINTENANCE BEVACIZUMAB MONOTHERAPY INCREASES HEMOGLOBIN (HGB) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG ADENOCARCINOMA (NSCLC-AD). JOURNAL OF THORACIC ONCOLOGY, 6(6), S962-S963.
  
• American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., & Giaccone, G. (2011). American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 2121-2127.
  
• Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer Kozak, M. M., Murphy, J. D., Schipper, M. L., Donington, J. S., Zhou, L., & Loo, B. W. (2011). Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(5), 920-926.
  
• Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked Gomez, S. L., Chang, E. T., Shema, S. J., Fish, K., Sison, J. D., & Wakelee, H. A. (2011). Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 20(3), 545-554.
  
• Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer Bazan, J. G., Chung, M. P., Eastham, D. V., Wakelee, H., Hara, W. Y., & Loo, B. W. (2011). Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S579-S580.
  
• Adjuvant chemotherapy for early stage non-small cell lung cancer. Patel, M. I., & Wakelee, H. A. (2011). Adjuvant chemotherapy for early stage non-small cell lung cancer. Frontiers in oncology, 1, 45-?.
  
• A Quantitative Assay of ERCC1 Expression in Circulating Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): A Potential Predictor of Treatment Response Das, M., Hsieh, B. H., Krivacic, R. T., Lazarus, N., Bennis, R., & Wakelee, H. A. (2010). A Quantitative Assay of ERCC1 Expression in Circulating Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): A Potential Predictor of Treatment Response. JOURNAL OF THORACIC ONCOLOGY, 5(12), S535-S535.
  
• Vascular Disrupting Agents Das, M., & Wakelee, H. (2010). Vascular Disrupting Agents. JOURNAL OF THORACIC ONCOLOGY, 5(12), S482-S483.
  
• A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies Wakelee, H. A., Gubens, M. A., Burns, M., Barbeau, S. L., Perkins, S., & Loehrer, P. J. (2010). A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 5(12), S528-S528.
  
• A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., & Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821-1825.
  
• Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial Chlebowski, R. T., Anderson, G. L., Manson, Ja. E., Schwartz, A. G., Wakelee, H., & Stefanick, M. L. (2010). Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 102(18), 1413-1421.
  
• AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487-495.
  
• Estrogen Alone and Lung Cancer in Postmenopausal Women Chlebowski, R., Anderson, G., Manson, J., Schwartz, A., Wakelee, H., & Stefanick, M. (2010). Estrogen Alone and Lung Cancer in Postmenopausal Women. GYNECOLOGIC ONCOLOGY, 117(2), 394-394.
  
• Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., & Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167-2175.
  
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., & Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376-381.
  
• Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review Clement-Duchene, C., & Wakelee, H. (2010). Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer A Review. JOURNAL OF THORACIC ONCOLOGY, 5(1), 129-139.
  
• Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir Chapman, C. H., Shen, J., Filion, E. J., Tran, P. T., Hara, W., & Green, J. (2009). Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir. JOURNAL OF THORACIC ONCOLOGY, 4(12), 1587-1589.
  
• Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress Wakelee, H., Loo, B. W., Kernstine, K. H., Putnam, J. B., Edelman, M. J., & Gandara, D. R. (2009). Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. CLINICAL LUNG CANCER, 10(6), 395-404.
  
• Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L., Stefanick, M. L., & Hubbell, F. A. (2009). Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. LANCET, 374(9697), 1243-1251.
  
• Quantification of pre-treatment metabolic tumor growth rate in lung cancer Eastham, D., Chapman, C. H., Rao, A. K., Balasubramanian, N., Quon, A., & Loo, B. W. (2009). Quantification of pre-treatment metabolic tumor growth rate in lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S733-S733.
  
• A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., & Wakelee, H. (2009). A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S674-S674.
  
• A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC) Wakelee, H. A., Dubey, S., Krupitskaya, Y., Osarogiagbon, R. U., Sanborn, R. E., & Natale, R. B. (2009). A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 4(9), S445-S445.
  
• Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., & Loo, B. W. (2009). Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S939-S939.
  
• Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors Chang, C. N., Zhou, L. Y., MacFarlane, G., Tran, P., Rao, A., & Loo, B. W. (2009). Excellent early local control with tumor volume adapted dosing of stereotactic body radiation therapy for pulmonary tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S938-S939.
  
• Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California Chang, E. T., Shema, S. J., Wakelee, H. A., Clarke, C. A., & Gomez, S. L. (2009). Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(8), 2248-2255.
  
• Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., & Gass, M. (2009). Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. JOURNAL OF CLINICAL ONCOLOGY, 27(18).
  
• Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Krupitskaya, Y., & Wakelee, H. A. (2009). Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(6), 597-605.
  
• A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC) Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene, C., & Wakelee, H. A. (2009). A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial Chlebowski, R. T., Schwartz, A., Wakelee, H., Anderson, G. L., Stefanick, M. L., & Gass, M. (2009). Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., & Obasaju, C. (2009). Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. ANNALS OF ONCOLOGY, 20(5), 850-856.
  
• Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Krupitskaya, Y., Eslamy, H. K., Nguyen, D. D., Kumar, A., & Wakelee, H. A. (2009). Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy. JOURNAL OF THORACIC ONCOLOGY, 4(3), 429-431.
  
• Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy Hsu, J. Y., & Wakelee, H. A. (2009). Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy. BIODRUGS, 23(5), 289-304.
  
• Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer? Eastham, D. V., Chapman, C. H., Rao, A. K., Narasimhan, B., Quon, A., & Loo, B. W. (2009). Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S446-S446.
  
• Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms Wei, K., Logan, A. C., Wakelee, H., Simon, M. C., & Kuo, C. J. (2008). Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms. BLOOD, 112(11), 183-184.
  
• Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer Wakelee, H., Kernstine, K., Vokes, E., Schiller, J., Baas, P., & Putnam Joe "Bill". (2008). Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 9(6), 346-351.
  
• Adjuvant chemotherapy for resected non-small cell lung cancer. Wakelee, H., & Chhatwani, L. (2008). Adjuvant chemotherapy for resected non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery, 20(3), 198-203.
  
• PEMETREXED DISODIUM FOR THE TREATMENT OF NSCLC: AN UPDATE Hsu, J. Y., & Wakelee, H. (2008). PEMETREXED DISODIUM FOR THE TREATMENT OF NSCLC: AN UPDATE. DRUGS OF TODAY, 44(9), 669-678.
  
• Sex differences in lung-cancer susceptibility: a smoke screen? Wakelee, H. A., Gomez, S. L., & Chang, E. T. (2008). Sex differences in lung-cancer susceptibility: a smoke screen?. LANCET ONCOLOGY, 9(7), 609-610.
  
• Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy Lynch, T. J., Blumenschein, G. R., Engelman, J. A., Espinoza-Delgado, I., Govindan, R., & Weitzman, A. (2008). Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. JOURNAL OF THORACIC ONCOLOGY, 3(6), S107-S112.
  
• Antibodies to vascular endothelial growth factor in non-small cell lung cancer Wakelee, H. (2008). Antibodies to vascular endothelial growth factor in non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 3(6), S113-S118.
  
• Complications of ablative therapies in lung cancer Padda, S., Kothary, N., Donington, J., Cannon, W., Loo, B. W., & Wakelee, H. (2008). Complications of ablative therapies in lung cancer. CLINICAL LUNG CANCER, 9(2), 122-126.
  
• Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress? Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., & Gandara, D. R. (2008). Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?. CLINICAL LUNG CANCER, 9(2), 85-91.
  
• Lung cancer presenting with amegakaryocytic thrombocytopenia. Witteles, W. H., Schrier, S. L., & Wakelee, H. A. (2008). Lung cancer presenting with amegakaryocytic thrombocytopenia. Journal of clinical oncology , 26(7), 1171-1174.
  
• Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors Loo, B. W., Shen, J., Quinlan-Davidson, S., Filion, E., Dieterich, S., & Le, Q. (2008). Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S467-S468.
  
• Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer Wakelee, H., Langer, C., Vokes, E., Schiller, J., Baas, P., & Gandara, D. R. (2008). Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer. CLINICAL LUNG CANCER, 9(1), 9-15.
  
• Review of erlotinib in the treatment of advanced non-small cell lung cancer. Ganjoo, K. N., & Wakelee, H. (2007). Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : targets & therapy, 1(4), 335-346.
  
• Metabolic tumor burden predicts for disease progression and death in lung cancer Lee, P., Weerasuriya, D. K., Lavori, P. W., Quon, A., Hara, W., & Loo, B. W. (2007). Metabolic tumor burden predicts for disease progression and death in lung cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(2), 328-333.
  
• Adjuvant chemotherapy of stage I non-small cell lung cancer in North America Gandara, D. R., Wakelee, H., Calhoun, R., & Jablons, D. (2007). Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. JOURNAL OF THORACIC ONCOLOGY, 2(7), S125-S127.
  
• Lung cancer incidence in never smokers Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., & West, D. W. (2007). Lung cancer incidence in never smokers. JOURNAL OF CLINICAL ONCOLOGY, 25(5), 472-478.
  
• Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Cabebe, E., & Wakelee, H. (2007). Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current treatment options in oncology, 8(1), 15-27.
  
• Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease Wakelee, H., Dubey, S., & Gandara, D. (2007). Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease. ONCOLOGIST, 12(3), 331-337.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM) Sikic, B. I., Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., & Piens, J. R. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM). EJC SUPPLEMENTS, 4(12), 106-107.
  
• Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors Le, Q.-T., Loo, B. W., Ho, A., Cotrutz, C., Koong, A. C., & Donington, J. (2006). Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 1(8), 802-809.
  
• A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma Roy, M. S., Le, Q.-T., Donington, J. S., & Wakelee, H. A. (2006). A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. CLINICAL LUNG CANCER, 8(2), 146-148.
  
• Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response Donington, J. S., Le, Q.-T., & Wakelee, H. A. (2006). Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. CLINICAL LUNG CANCER, 8(1), 22-29.
  
• Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial Wakelee, H. A., Schiller, J. H., & Gandara, D. R. (2006). Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial. CLINICAL LUNG CANCER, 8(1), 18-21.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., & Sikic, B. I. (2006). A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 131S-131S.
  
• Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594 Wakelee, H. A., Wang, W., Schiller, J. H., Langer, C. J., Sandler, A. B., & Johnson, D. H. (2006). Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY, 1(5), 441-446.
  
• Sunitinib: A newly approved small-molecule inhibitor of angiogenesis Cabebe, E., & Wakelee, H. (2006). Sunitinib: A newly approved small-molecule inhibitor of angiogenesis. DRUGS OF TODAY, 42(6), 387-398.
  
• Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990 Wakelee, H. A., Bernardo, P., Johnson, D. H., & Schiller, J. H. (2006). Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. CANCER, 106(10), 2208-2217.
  
• An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers Le, Q. T., Chen, E., Salim, A., Cao, H. B., Kong, C. S., & Giaccia, A. J. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. CLINICAL CANCER RESEARCH, 12(5), 1507-1514.
  
• Second- and third-line treatments in non-small cell lung cancer. Kumar, A., & Wakelee, H. (2006). Second- and third-line treatments in non-small cell lung cancer. Current treatment options in oncology, 7(1), 37-49.
  
• A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., & Sikic, B. I. (2005). A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies. CLINICAL CANCER RESEARCH, 11(24), 9029S-9029S.
  
• Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer Wakelee, H. A., & Schiller, J. H. (2005). Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer. CLINICAL LUNG CANCER, 7, S31-S38.
  
• Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors Wakelee, H. A., & Sikic, B. I. (2005). Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors. CLINICAL LUNG CANCER, 7, S6-S12.
  
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.
  
• Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC) Wakelee, H., Middleton, G., Dunlop, D., Kelly, C., Ramlau, R., & Loewen, G. (2005). Effect of bexarotene on vinorelbine and cisplatin pharmacokinetics during a Phase I study in patients with advanced non-small cell lung cancer (NSCLC). LUNG CANCER, 49, S274-S274.
  
• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer Wakelee, H., & Fisher, G. A. (2005). A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 23(3), 241-242.
  
• Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 Wakelee, H. A., Stephenson, P., Keller, S. M., Wagner, H., Herskovic, A., & Johnson, D. H. (2005). Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. LUNG CANCER, 48(3), 389-397.
  
• A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S-234S.
  
• A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies Wakelee, H., Adjei, A. A., Keer, H., Halsey, J., Hanson, L., & Sikic, B. I. (2005). A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 227S-227S.
  
• Docetaxel in advanced non-small cell lung cancer Wakelee, H., Ramalingam, S., & Belani, C. P. (2005). Docetaxel in advanced non-small cell lung cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(1), 13-24.
  
• Optimizing first-line treatment options for patients with advanced NSCLC Wakelee, H., & Belani, C. P. (2005). Optimizing first-line treatment options for patients with advanced NSCLC. ONCOLOGIST, 10, 1-10.
  
• Results of a phase I dose escalation study using single fraction stereotactic radiosurgery (SFSR) for lung tumors Le, Q. X., Ho, A., Cotrutz, C., Loo, B., Petrik, D., & Donington, J. S. (2005). Results of a phase I dose escalation study using single fraction stereotactic radiosurgery (SFSR) for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), S226-S226.
  
• Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial. Le, Q. T., Ho, A., Cotrutz, C., Wakelee, H., Kee, S. T., & Whyte, R. I. (2004). Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 673S-673S.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., & Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S-248S.
  
• Novel approaches for the treatment of small cell lung cancer Wakelee, H., & Kelly, K. (2004). Novel approaches for the treatment of small cell lung cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 18(2), 499-?.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., & Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S-6103S.
  
• Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines HAWS, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., & Wine, J. J. (1996). Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 270(5), C1544-C1555.